Therapeutic Silencing of KRAS using Systemically Delivered siRNAs

Despite being amongst the most common oncogenes in human cancer, to date there are no effective clinical options for inhibiting KRAS activity. We investigated whether systemically delivered KRAS siRNAs have therapeutic potential in KRAS mutated cancer models. We identified KRAS siRNA sequences with...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Mol Cancer Ther
Egile Nagusiak: Pecot, Chad V., Wu, Sherry Y., Bellister, Seth, Filant, Justyna, Rupaimoole, Rajesha, Hisamatsu, Takeshi, Bhattacharya, Rajat, Maharaj, Anshumaan, Azam, Salma, Rodriguez-Aguayo, Cristian, Nagaraja, Archana S., Morelli, Maria Pia, Gharpure, Kshipra M., Waugh, Trent A., Gonzalez-Villasana, Vianey, Zand, Behrouz, Dalton, Heather J., Kopetz, Scott, Lopez-Berestein, Gabriel, Ellis, Lee M., Sood, Anil K.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2014
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4416486/
https://ncbi.nlm.nih.gov/pubmed/25281617
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-14-0074
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak